Newsfeeds Archive - Page 2 of 6

1 minute read

QIAGEN Sees FY24 EPS $2.10 CER Vs $2.20 CER Est.; Revenue Of At Least $2B CER Vs 2.06B CER Est.

February 6, 5:23 PM

For 2024, QIAGEN has set an outlook for net sales of at least $2.0 billion CER. This reflects full-year total growth of at least 2% CER, with solid mid-single-digit CER sales growth in H2 2024 in the non‑COVID portfolio

QGEN

10 minute read

Earnings

Earnings Scheduled For February 6, 2024

By Benzinga Insights

February 6, 6:42 AM

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

AAT

1 minute read

Earnings

Earnings Preview: Qiagen

By Benzinga Insights

February 5, 11:02 AM

Qiagen (NYSE:QGEN) is set to give its latest quarterly earnings report on Tuesday, 2024-02-06. Here’s what investors need…

QGEN

3 minute read

QIAGEN Announces Partnership With Penn State University To Advance Microbiome Sciences

By Benzinga Newsdesk

January 25, 11:01 AM

QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the

QGEN

2 minute read

Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion

By Vandana Singh

January 17, 4:21 PM

Goldman Sachs upgrades Twist Bioscience as Express Genes launch addresses SynBio division's gross margin issues. With 5-7 days gene delivery, TWST taps into a previously inaccessible market, enhancing revenue and profit margins.

1 minute read

QIAGEN Bags FDA Clearance of NeuMoDx CT/NG Assay for Both NeuMoDx 96 and 288 Molecular Systems

By Benzinga Newsdesk

January 8, 3:03 AM

QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced the U.S. Food and Drug Administration (FDA) clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical

QGEN

1 minute read

QIAGEN To Return ~$300M To Shareholders Through A Synthetic Share Repurchase

By Charles Gross

January 7, 3:36 PM

QIAGEN N.V. announces a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock

QGEN